IGM Biosciences is developing a different class of antibodies to improve on the classic IgG antibodies. Their most advanced project, aplitabart, is being tested in a clinical trial for metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback